Evidence map›Paper›PMID 26712327›Full record

ArticleTrials2015

Making smart investment decisions in clinical research.

Nick Bansback, Edward Keystone, James O'Dell, Ciaran S Phibbs, Keri Hannagan, Mary Brophy, Aslam Anis

Registry-linked trialAbstract read
In one paragraph

Article in Trials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00405275 (CSP #551 - Rheumatoid Arthritis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00405275 nacompletednot on this map

CSP #551 - Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

TypeinterventionalSponsorUS Department of Veterans AffairsRan2007 to 2012Enrolled353ConditionsRheumatoid ArthritisArmsEtanercept, methotrexate, Sulfasalazine, Hydroxychloroquine, Placebo, triple
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nick BansbackSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. nick.bansback@ubc.ca.
Edward KeystoneUniversity of Toronto, Toronto, Canada. edkeystone@mtsinai.on.ca.
James O'DellNebraska-Western Iowa Health Care System, Omaha, USA. jrodell@unmc.edu.
Ciaran S PhibbsHealth Economics Resource Center and the Center for Health Care Evaluation, Veterans Affairs Palo Alto Health Care System, Menlo Park, CA, USA. cphibbs@stanford.edu.
Keri HannaganVA Cooperative Studies Program Coordinating Center, Boston, USA. Keri.Hannagan@va.gov.
Mary BrophyVA Cooperative Studies Program Coordinating Center, Boston, USA. Mary.Brophy@va.gov.
Aslam AnisSchool of Population and Public Health, University of British Columbia, Vancouver, BC, Canada. aslam.anis@ubc.ca.

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

unlabelledA recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100's of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs.

trial registrationNCT00405275 , registered 29 November 2006.

Indexed as

Drug CostsResearch Support as TopicAntirheumatic AgentsArthritis, RheumatoidBiological ProductsCost-Benefit AnalysisCost SavingsDrug IndustryDrug Therapy, CombinationEvidence-Based MedicineHumansPractice Patterns, Physicians'Randomized Controlled Trials as TopicTreatment OutcomeAntirheumatic AgentsBiological Products

Identifiers

PMID26712327
PMCPMC4693420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.